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So the Editor: In recent years, the introduction (1) of drug-
luting stents (DES) during percutaneous coronary interventions
PCI) has been one of the major breakthroughs in interventional
rocedures. Several observational and randomized studies have
hown a significantly lower restenosis rate with DES compared
ith bare-stent technology. Sirolimus-eluting stents (SES) or
aclitaxel-eluting stents (PES) stents also substantially reduce the
eed for repeat revascularization procedures compared with stan-
ard stent technology (2–5). However, late safety outcome of these
ew devices is not well established. Late stent thrombosis, not seen
n the first series of studies (1–5), has been recently reported (6,7)
nd was associated with major adverse cardiac events. Even though
meta-analysis of randomized studies and registries confirmed the
fficacy and safety of DES (8), these studies were not powered to
etect any increase in late-stent thrombosis. Furthermore, in those
tudies, stent thrombosis (SET) was not equal and appropriately
efined; more importantly, none of the cited studies included SET
s a prespecified end point. Therefore, we sought to investigate the
ncidence of SET in a DES population (9) included prospectively
n the multicenter and controlled Argentine Randomized Trial of
oronary Stents versus Bypass Surgery (ERACI III) trial.
From June 2002 to December 2004, 225 patients treated with
CI and DES in five centers in Buenos Aires meeting the clinical
nd angiographic criteria of the ERACI II trial (10) were prospec-
ively and consecutively included in the ERACI III study. The
nclusion criteria of the ERACI studies were previously reported
10). All patients had multiple-vessel disease and were treated with
t least one DES, SES, or PES in equal proportion (Cypher,
ordis, Johnson and Johnson, Miami Lakes, Florida; and
AXUS, Boston Scientific Corp., Natick, Massachusetts). The
nd points of the ERACI III study were to compare major and
inor cardiac adverse events at one, two, three, and five years of
ollow-up between the ERACI III DES patients (n  225) and
RACI II PCI (n  225) and ERACI II CABG study patients
n  225). Comparison of coronary stent thrombosis (SET)
etween the ERACI III and ERACI II PCI study arm (bare stent)
as one of the secondary end points of this study. The purpose of
his study was to analyze the incidence of SET during the first 30
ays and during follow-up in the ERACI III study patients.
Stent thrombosis was defined as follows:
. Suspected stent thrombosis (SST), in which the patient
experienced unexpected cardiac or sudden death or had a
ST-segment elevation myocardial infarction (STEMI) that
correlated with the area of DES placement. Patients having
non–STEMI myocardial infarctions or whose electrocardio-
grams at the moment of the acute event could not be reviewed
were not included in this category.
. Confirmed stent thrombosis (CST), in which the patient had
angiographically documented stent thrombosis with Throm-
bolysis In Myocardial Infarction (TIMI) flow grade 0 or 1 or
the presence of flow-limiting thrombus (TIMI flow grade 1 or
2). Both SST and CST were counted as definite SET. Llinical follow-up was made by personal interview or by phone
nd was obtained in 100% of DES patients during the first 30 days
nd in 96% of all patients at one year. Patients with an unexpected
ardiac or sudden death were included as SST only if the event was
ertified by a physician present during or immediately after the
cute event. Clinical events were adjudicated by a clinical events
ommittee. All PCI procedures were performed according to current
uidelines of interventional procedures. Patients were pretreated with
oading doses of 300 mg of clopidogrel and aspirin, and dual
ntiplatelet therapy was maintained for three and six months after the
rocedure in SES- and PES-eluted stents, respectively.
Baseline clinical and angiographic characteristics of the ERACI
II study are described in Table 1.
During the 18.3  8.8 months of follow-up (range 5 to 36
onths) from the 225 patients included in the ERACI III study,
e identified 7 patients with SET (3.1%). The time course of this
henomenon was between 3 and 927 days after stent deployment.
hree patients had SET during the first 30 days after the index
rocedure, three other patients during the first year afterward, and
he last patient 31 months afterward (Table 2). Confirmed stent
hrombosis was detected in five patients (2.2%) and SST in the
ther two (0.9%). Of those patients with SST, one without
revious symptoms developed an extensive STEMI (V1 to V6)
ith subsequent death 8 h after symptom onset (Patient #6, SES
n left anterior descending and left circumflex, Table 2) and the
ther had acute pulmonary edema and died 1 h later under cardiac
rrest (Patient #7, SES in left main coronary artery, Table 2). Four
atients with CST also were treated with bare stent in another
essel, and all of them were patent at the time of the angiography
Table 2). Six of the seven SETs (86%) were related to clopidogrel
able 1. Baseline Demographic, Clinical, and Angiographic
haracteristics of the Overall Population and With Stent
hrombosis
ERACI III
(n  225)
Stent
Thrombosis
(n  7)
ge (yrs) 65.5  10.9 65.568  7.25
en (%) 83.5 100
ypertension (%) 79.5 100
iabetes (%) 20.4 28
moker (%) 68.4 85
table angina (%) 26.3 42
nstable angina (%) 73.7 58
M (%) 5.7 14
vessels (%) 61.7 42
vessels (%) 38.3 58
tent length per patient (mm) 36 37
tent diameter (mm) 2.93  0.3 2.71  0.26
tent per patient 1.8 2.1
tent design (%)
Sirolimus-eluting stent 52 58
Paclitaxel-eluting stent 48 42M  left main coronary artery.
Table 2. Characteristics of Patients With Stent Thrombosis
Patient
No.
Age (yrs),
Gender CST/SST
DES
Design
Time to DES
Implantation
Bare
Stent
Patent Treated Vessel
Stent
Diameter
(mm)
Stent
Length
(mm) Notes
Clinical
Presentation
Clinical
Outcome at
Hospital
Discharge
1 70, Male CST PES 7 days Yes LAD 2.5 16 Clopidogrel stopped 3
days prior
STEMI Death
2 73, Male CST PES 204 days Yes LAD 3.0 24 Aspirin and
clopidogrel stopped
7 days before
surgery
STEMI Alive
3 75, Male CST PES 49 days Yes LCX 2.5 16 Aspirin and
clopidogrel stopped
4 days for
haematuria and
surgery
STEMI Alive
4 57, Male CST SES 3 days — LAD 3.0 33 Clopidogrel stopped 2
days prior
STEMI Alive
5 63, Male CST SES 927 days Yes LAD 2.5 33 Aspirin and
clopidogrel stopped
for 45 days for
gastrointestinal
hemorrhage and
surgery
STEMI Alive
6 60, Male SST SES 227 days — LAD and LCX 2.5 23 Aspirin and
clopidogrel stopped
7 days prior
STEMI Death
7 66, Male SST SES 5 days — LM 3.0 18 Aspirin and
clopidogrel not
stopped
APE Death
APE  acute pulmonary edema; CST  confirmed stent thrombosis; DES  drug-eluting stent; LAD  left anterior descending artery; LCX  left circumflex; LM  left main; PES  paclitaxel-eluting stent; SES  sirolimus-eluting
stent; SST  suspected stent thrombosis; STEMI  ST-segment elevation myocardial infarction.
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January 3, 2006:205–15essation; Table 2 shows the time between discontinuation of
lopidogrel and SET. Early (less than three months with SES and
ix months with PES) discontinuation of dual antiplatelet therapy
as required in seven patients, one of whom developed SET,
hereas late discontinuation was observed in eight patients, three
f whom had SET. Two patients also stopped clopidogrel early,
nd both developed SET.
Stent thrombosis was always associated with major adverse
vents: three patients died (43%) and four patients developed an
xtensive STEMI (57%). Finally, both DES designs had similar
ncidence of SET (1.9% with SES and 1.5% with PES).
With current antiplatelet therapy, stent thrombosis after coro-
ary bare stent therapy is a rare event after hospital discharge; in
act, in the ERACI II study stent arm, patients were under
iclopidine during one month and after hospital discharge, and no
atient had SET during the first year of follow-up (10). Further-
ore, in the present study, among patients simultaneously treated
ith DES and bare stent, CST was present only at the place of
ES implantation. The ERACI III study data suggested that
ET with DES is unexpected and can occur either early after
ospital discharge or very late in the follow-up phase, when many
atients have discontinued antiplatelet therapy. The clinical im-
lications of these findings suggest a potential concern with the
urrent widespread use of DES and show the need for larger
ontrolled studies.
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Noncalcified and Calcified Coronary Plaque Detection by Contrast-Enhanced
A Study of Interobserver Agreemento the Editor: Contrast-enhanced multi-detector computed to-
ography (MDCT) coronary angiography permits reliable visual-
zation of coronary arteries. Recent studies showed a high sensi-
ivity and specificity of 16-slice MDCT for the detection of
emodynamically significant coronary stenosis (1,2). In addition to
uminal narrowing, it was early recognized that MDCT also
isualizes the diseased coronary arterial wall (3). Two recent
tudies with 16-slice MDCT showed sensitivity of 75% and 82%
nd specificity of 88% and 92% to detect coronary plaque using
ntravascular ultrasound as the standard of reference (4,5). The
oal of our study was to establish the interobserver reproducibility
f coronary plaque detection by 16-slice MDCT.
We enrolled 45 consecutive patients (37 men; mean age, 56 
years; mean heart rate during the scan, 55  6 beats/min) who
nderwent contrast-enhanced MDCT before coronary angiogra-
hy as part of a research protocol. Patients were scheduled for aith a heart rate 65 beats/min were included in the evaluation.
atients with allergic reaction to iodinated contrast, atrial fibrilla-
ion, or creatinine serum level1.5 mg/ml were excluded from the
tudy. The institutional review boards approved the study protocol,
nd patients’ written informed consents were obtained.
Examinations were performed with a 16-slice MDCT scanner
Siemens, Forchheim, Germany; tube current, 550 mA; tube
oltage, 120 kVp; collimation, 16 0.75 mm; gantry rotation, 375
s; contrast, 90 ml iopromide 370 mgI/ml; slice thickness, 1 mm
t 0.5-mm intervals; kernel B35f). An oral beta-blocker (atenolol
00 mg) was administered one hour before the scan to 38 (84%)
atients with a heart rate 60 beats/min. Sublingual nitroglycerin
glycerol trinitrate 0.8 mg) was administered immediately before
he scan. Prospectively, electrocardiographically triggered tube
urrent modulation was applied during all examinations.
The MDCT datasets (axial, multiplanar reformatted, and
aximum-intensity projection images) were evaluated by two
